Expression level and clinical significance of HMGB1-TLR4-IL-23-IL-17A axis in serum of patients with psoriasis vulgaris
10.3969/j.issn.1000-484X.2024.07.022
- VernacularTitle:HMGB1-TLR4-IL-23-IL-17A轴在寻常型银屑病患者血清中的表达水平及临床意义
- Author:
Xiaofeng ZHU
1
;
Yawen LIN
;
Yue DOU
;
Jing WANG
;
Haiyou HU
;
Yu GAO
;
Lei MA
Author Information
1. 滨州医学院附属医院,滨州 256603
- Keywords:
Psoriasis;
HMGB1;
TLR4;
IL-23;
IL-17A
- From:
Chinese Journal of Immunology
2024;40(7):1479-1483
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression level and clinical significance of HMGB1-TLR4-IL-23-IL-17A axis in se-rum of patients with psoriasis vulgaris.Methods:The expression levels of HMGB1,TLR4,IL-23 and IL-17A in serum of 60 patients with psoriasis vulgaris and 30 healthy volunteers were detected by ELISA.In addition,the differences of cytokines expression levels between moderate and severe psoriasis patients were compared,and the correlation between the expression levels of cytokines and the disease severity expressed by psoriasis area and severity index(PASI)were analyzed.The differences of expression levels of HMGB1-TLR4-IL-23-IL-17A axis before and after IL-17A inhibitor induction treatment were detected and compared in 22 moderate to severe psoriasis patients reached PASI75 and higher level.Results:The expression levels of serum HMGB1,TLR4,IL-23 and IL-17A in patients with psoriasis were obviously higher than those of healthy controls.Moreover,the expression levels of serum HMGB1,TLR4,IL-23 and IL-17A were even elevated in severe patients compared with moderate patients,and were positively correlated with PASI score.After induction treatment of IL-17A inhibitor,the expression levels of HMGB1-TLR4-IL-23-IL-17A aixs decreased significantly in serum of patients with psoriasis.Conclusion:HMGB1-TLR4-IL-23-IL-17A axis is highly expressed in patients with psoriasis vulgaris,and positively related to the disease severity,which may be involved in the disease process of psoriasis vulgaris and provide a new idea for the immunotherapy of psoriasis.
